Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023 [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
Global COVID-19 Testing Market to Reach $5.8 Billion by 2030 The global market for COVID-19 Testing estimated at US$19.9 Billion in the year 2023, is projected to reach a revised size of US$5.8 Billion by 2030, growing at a CAGR of -14.2% over the analysis period 2023-2030. COVID-19 testing has become integral in controlling the spread of the virus, witnessing significant growth due to the rising incidence of the coronavirus. Various types of tests are employed, including molecular tests such as RT-PCR, which currently dominate the market. Rapid tests have also emerged as crucial tools in containing the virus due to their quick turnaround times. RT-PCR Assay Kits, one of the segments analyzed in the report, is projected to record -14.9% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Immunoassay Test Strips/cassettes segment is estimated at -12.5% CAGR for the next 8-year period. Immunoassays, particularly antibody tests, are experiencing rapid
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune, Inc. (NASDAQ: ALT) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- Altimmune Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Influenza Vaccine Market size is set to grow by USD 2.93 billion from 2023-2027, increasing prevalence and incidence of influenza boost the market, Technavio [Yahoo! Finance]Yahoo! Finance
- Buy Altimmune's Potential Market Disruption With Pemvidutide [Seeking Alpha]Seeking Alpha
- Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
ALT
Earnings
- 3/27/24 - Miss
ALT
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form S-8
- 3/27/24 - Form 10-K
- ALT's page on the SEC website